180 related articles for article (PubMed ID: 35923111)
21. Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma.
Weed DT; Vella JL; Reis IM; De la Fuente AC; Gomez C; Sargi Z; Nazarian R; Califano J; Borrello I; Serafini P
Clin Cancer Res; 2015 Jan; 21(1):39-48. PubMed ID: 25320361
[TBL] [Abstract][Full Text] [Related]
22. Histone Methyltransferase G9a Drives Chemotherapy Resistance by Regulating the Glutamate-Cysteine Ligase Catalytic Subunit in Head and Neck Squamous Cell Carcinoma.
Liu CW; Hua KT; Li KC; Kao HF; Hong RL; Ko JY; Hsiao M; Kuo ML; Tan CT
Mol Cancer Ther; 2017 Jul; 16(7):1421-1434. PubMed ID: 28265008
[TBL] [Abstract][Full Text] [Related]
23. Blockade of TIGIT/CD155 Signaling Reverses T-cell Exhaustion and Enhances Antitumor Capability in Head and Neck Squamous Cell Carcinoma.
Wu L; Mao L; Liu JF; Chen L; Yu GT; Yang LL; Wu H; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
Cancer Immunol Res; 2019 Oct; 7(10):1700-1713. PubMed ID: 31387897
[TBL] [Abstract][Full Text] [Related]
24. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM
Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323
[TBL] [Abstract][Full Text] [Related]
25. Intratumoral CD103
Ren S; Lan T; Wu F; Chen S; Jiang X; Huo C; Li Z; Xie S; Wu D; Wang R; Li Y; Qiu L; Huang G; Li S; Wang X; Cen M; Cai T; Lin Z; Li J; Li B
Cancer Commun (Lond); 2023 Oct; 43(10):1143-1163. PubMed ID: 37658605
[TBL] [Abstract][Full Text] [Related]
26. Spatial and Single-Cell Transcriptomics Reveal a Cancer-Associated Fibroblast Subset in HNSCC That Restricts Infiltration and Antitumor Activity of CD8+ T Cells.
Li C; Guo H; Zhai P; Yan M; Liu C; Wang X; Shi C; Li J; Tong T; Zhang Z; Ma H; Zhang J
Cancer Res; 2024 Jan; 84(2):258-275. PubMed ID: 37930937
[TBL] [Abstract][Full Text] [Related]
27. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
[TBL] [Abstract][Full Text] [Related]
28. Interference with the bromodomain epigenome readers drives p21 expression and tumor senescence.
Webber LP; Yujra VQ; Vargas PA; Martins MD; Squarize CH; Castilho RM
Cancer Lett; 2019 Oct; 461():10-20. PubMed ID: 31265875
[TBL] [Abstract][Full Text] [Related]
29.
Cheng Y; Lemke-Miltner CD; Wongpattaraworakul W; Wang Z; Chan CHF; Salem AK; Weiner GJ; Simons AL
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33060147
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of MEK with trametinib enhances the efficacy of anti-PD-L1 inhibitor by regulating anti-tumor immunity in head and neck squamous cell carcinoma.
Kang SH; Keam B; Ahn YO; Park HR; Kim M; Kim TM; Kim DW; Heo DS
Oncoimmunology; 2019; 8(1):e1515057. PubMed ID: 30546955
[TBL] [Abstract][Full Text] [Related]
31. BMI1 Inhibition Eliminates Residual Cancer Stem Cells after PD1 Blockade and Activates Antitumor Immunity to Prevent Metastasis and Relapse.
Jia L; Zhang W; Wang CY
Cell Stem Cell; 2020 Aug; 27(2):238-253.e6. PubMed ID: 32697949
[TBL] [Abstract][Full Text] [Related]
32. PVT1 inhibition stimulates anti-tumor immunity, prevents metastasis, and depletes cancer stem cells in squamous cell carcinoma.
Qin Z; Zhang W; Liu S; Wang Y; Peng X; Jia L
Cell Death Dis; 2023 Mar; 14(3):187. PubMed ID: 36894542
[TBL] [Abstract][Full Text] [Related]
33. Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of eIF4E expression.
Gao Z; Yuan T; Zhou X; Ni P; Sun G; Li P; Cheng Z; Wang X
Cancer Biol Ther; 2018 May; 19(5):407-415. PubMed ID: 29333921
[TBL] [Abstract][Full Text] [Related]
34. Combination of downregulating FEN1 and PD-1 blockade enhances antitumor activity of CD8+ T cells against HNSCC cells in vitro.
Wang X; Xu S; Fu T; Wu Y; Sun W
J Oral Pathol Med; 2023 Oct; 52(9):834-842. PubMed ID: 37728572
[TBL] [Abstract][Full Text] [Related]
35. PD-L1 and MRN synergy in platinum-based chemoresistance of head and neck squamous cell carcinoma.
Shen B; Huang D; Ramsey AJ; Ig-Izevbekhai K; Zhang K; Lajud SA; O'Malley BW; Li D
Br J Cancer; 2020 Mar; 122(5):640-647. PubMed ID: 31853007
[TBL] [Abstract][Full Text] [Related]
36. TAM family receptors in conjunction with MAPK signalling are involved in acquired resistance to PI3Kα inhibition in head and neck squamous cell carcinoma.
Ruicci KM; Meens J; Plantinga P; Stecho W; Pinto N; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Howlett CJ; Boutros PC; Ailles L; Nichols AC
J Exp Clin Cancer Res; 2020 Oct; 39(1):217. PubMed ID: 33059733
[TBL] [Abstract][Full Text] [Related]
37. EREG-driven oncogenesis of Head and Neck Squamous Cell Carcinoma exhibits higher sensitivity to Erlotinib therapy.
Liu S; Wang Y; Han Y; Xia W; Zhang L; Xu S; Ju H; Zhang X; Ren G; Liu L; Ye W; Zhang Z; Hu J
Theranostics; 2020; 10(23):10589-10605. PubMed ID: 32929368
[No Abstract] [Full Text] [Related]
38. High Abundance of Intratumoral γδ T Cells Favors a Better Prognosis in Head and Neck Squamous Cell Carcinoma: A Bioinformatic Analysis.
Lu H; Dai W; Guo J; Wang D; Wen S; Yang L; Lin D; Xie W; Wen L; Fang J; Wang Z
Front Immunol; 2020; 11():573920. PubMed ID: 33101298
[TBL] [Abstract][Full Text] [Related]
39. Blockade of MCP-1/CCR4 signaling-induced recruitment of activated regulatory cells evokes an antitumor immune response in head and neck squamous cell carcinoma.
Sun W; Li WJ; Wei FQ; Wong TS; Lei WB; Zhu XL; Li J; Wen WP
Oncotarget; 2016 Jun; 7(25):37714-37727. PubMed ID: 27177223
[TBL] [Abstract][Full Text] [Related]
40. Pharmacological inhibition of CDK7 by THZ1 impairs tumor growth in p53-mutated HNSCC.
Ge H; Yao Y; Jiang Y; Wu X; Wang Y
Oral Dis; 2022 Apr; 28(3):611-620. PubMed ID: 33503275
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
